KalVista Pharmaceuticals (KALV) Common Equity (2016 - 2024)
Historic Common Equity for KalVista Pharmaceuticals (KALV) over the last 10 years, with Q4 2024 value amounting to $164.4 million.
- KalVista Pharmaceuticals' Common Equity changed N/A to $164.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $164.4 million, marking a year-over-year change of. This contributed to the annual value of $206.6 million for FY2024, which is N/A changed from last year.
- According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Common Equity is $164.4 million.
- KalVista Pharmaceuticals' Common Equity's 5-year high stood at $206.6 million during Q2 2024, with a 5-year trough of $58.6 million in Q1 2021.
- Moreover, its 4-year median value for Common Equity was $102.1 million (2020), whereas its average is $116.0 million.
- Per our database at Business Quant, KalVista Pharmaceuticals' Common Equity tumbled by 3474.43% in 2021 and then surged by 2401.69% in 2024.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Common Equity stood at $65.0 million in 2020, then fell by 9.87% to $58.6 million in 2021, then skyrocketed by 95.42% to $114.4 million in 2023, then skyrocketed by 43.61% to $164.4 million in 2024.
- Its last three reported values are $164.4 million in Q4 2024, $134.0 million for Q4 2024, and $172.8 million during Q3 2024.